Back to top
more

Immuneering (IMRX)

(Delayed Data from NSDQ)

$1.87 USD

1.87
152,235

+0.01 (0.54%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $1.86 -0.01 (-0.53%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

by Zacks Equity Research

The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

by Zacks Equity Research

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

by Zacks Equity Research

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 5.56% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?

by Zacks Equity Research

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 210.2% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 13.79% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

What Makes Immuneering Corporation (IMRX) a New Buy Stock

by Zacks Equity Research

Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 148% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104

by Zacks Equity Research

Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 223.5% upside potential for Immuneering Corporation (IMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -14.71% and 9.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is a Surprise Coming for Immuneering (IMRX) This Earnings Season?

by Zacks Equity Research

Immuneering (IMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Immuneering (IMRX) Ahead of Earnings?

by Zacks Equity Research

Immuneering (IMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.